

Table 7. Treatment recommendations for HCV-monoinfected or HCV/HIV-coinfected patients with chronic hepatitis C without cirrhosis, including treatment-naïve patients (defined as patients who have never been treated for their HCV infection) and treatment-experienced patients (defined as patients who were previously treated with pegylated IFN- α and ribavirin; pegylated IFN- α , ribavirin and sofosbuvir; or sofosbuvir and ribavirin).

Patients	Prior treatment experience	SOF/VEL	GLE/PIB	SOF/VEL/VOX	SOF/LDV	GZR/EBR	OBV/PTV/r + DSV
Genotype 1a	Treatment-naïve	12 wk	8 wk	No	8-12 wk	12 wk (HCV RNA \leq 800,000 IU/ml)	No
	Treatment-experienced	12 wk	8 wk	No	No	12 wk (HCV RNA \leq 800,000 IU/ml)	No
Genotype 1b	Treatment-naïve	12 wk	8 wk	No	8-12 wk	8 wk (F0-F2) 12 wk (F3)	8 wk (F0-F2) 12 wk (F3)
	Treatment-experienced	12 wk	8 wk	No	12 wk	12 wk	12 wk
Genotype 2	Treatment-naïve	12 wk	8 wk	No	No	No	No
	Treatment-experienced	12 wk	8 wk	No	No	No	No
Genotype 3	Treatment-naïve	12 wk	8 wk	No	No	No	No
	Treatment-experienced	12 wk	12 wk	No	No	No	No
Genotype 4	Treatment-naïve	12 wk	8 wk	No	12 wk	12 wk (HCV RNA \leq 800,000 IU/ml)	No
	Treatment-experienced	12 wk	8 wk	No	No	No	No
Genotype 5	Treatment-naïve	12 wk	8 wk	No	12 wk	No	No
	Treatment-experienced	12 wk	8 wk	No	No	No	No
Genotype 6	Treatment-naïve	12 wk	8 wk	No	12 wk	No	No
	Treatment-experienced	12 wk	8 wk	No	No	No	No

DAA, direct-acting antiviral; DSV, dasabuvir; EBR, elbasvir; GLE, glecaprevir; GZR, grazoprevir; HCV, hepatitis C virus; HIV, human immunodeficiency virus; LDV, ledipasvir; OBV, ombitasvir; PIB, pibrentasvir; PTV, paritaprevir; r, ritonavir; SOF, sofosbuvir; VEL, velpatasvir; VOX: voxilaprevir.

Table 8. Treatment recommendations for HCV-monoinfected or HCV/HIV-coinfected patients with compensated (Child-Pugh A) cirrhosis, including treatment-naïve patients (defined as patients who have never been treated for their HCV infection) and treatment-experienced patients (defined as patients who were previously treated with pegylated IFN- α and ribavirin; pegylated IFN- α , ribavirin and sofosbuvir; or sofosbuvir and ribavirin).

Patients	Prior treatment experience	SOF/VEL	GLE/PIB	SOF/VEL/VOX	SOF/LDV	GZR/EBR	OBV/PTV/r + DSV
Genotype 1a	Treatment-naïve	12 wk	12 wk	No	12 wk	12 wk (HCV RNA \leq 800,000 IU/ml)	No
	Treatment-experienced	12 wk	12 wk	No	No	12 wk (HCV RNA \leq 800,000 IU/ml)	No
Genotype 1b	Treatment-naïve	12 wk	12 wk	No	12 wk	12 wk	12 wk
	Treatment-experienced	12 wk	12 wk	No	12 wk	12 wk	12 wk
Genotype 2	Treatment-naïve	12 wk	12 wk	No	No	No	No
	Treatment-experienced	12 wk	12 wk	No	No	No	No
Genotype 3	Treatment-naïve	No	12 wk	12 wk	No	No	No
	Treatment-experienced	No	16 wk	12 wk	No	No	No
Genotype 4	Treatment-naïve	12 wk	12 wk	No	12 wk	12 wk (HCV RNA \leq 800,000 IU/ml)	No
	Treatment-experienced	12 wk	12 wk	No	No	No	No
Genotype 5	Treatment-naïve	12 wk	12 wk	No	12 wk	No	No
	Treatment-experienced	12 wk	12 wk	No	No	No	No
Genotype 6	Treatment-naïve	12 wk	12 wk	No	12 wk	No	No
	Treatment-experienced	12 wk	12 wk	No	No	No	No

DAA, direct-acting antiviral; DSV, dasabuvir; EBR, elbasvir; GLE, glecaprevir; GZR, grazoprevir; HCV, hepatitis C virus; HIV, human immunodeficiency virus; LDV, ledipasvir; OBV, ombitasvir; PIB, pibrentasvir; PTV, paritaprevir; r, ritonavir; SOF, sofosbuvir; VEL, velpatasvir; VOX: voxilaprevir.